Zevra Therapeutics
ZVRA
166 hedge funds and large institutions have $379M invested in Zevra Therapeutics in 2025 Q3 according to their latest regulatory filings, with 56 funds opening new positions, 52 increasing their positions, 37 reducing their positions, and 10 closing their positions.
460% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 10
95% more call options, than puts
Call options by funds: $24.8M | Put options by funds: $12.8M
41% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 37
38% more funds holding
Funds holding: 120 → 166 (+46)
19% more capital invested
Capital invested by funds: $319M → $379M (+$60.6M)
4.89% more ownership
Funds ownership: 66.19% → 71.08% (+4.9%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$10.5M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$9.15M |
| 3 |
RA
Royce & Associates
New York
|
+$6.93M |
| 4 |
D.E. Shaw & Co
New York
|
+$5.38M |
| 5 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$5.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$19.5M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$17.3M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$11.4M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.57M |
| 5 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
-$6.3M |
ZVRA Hedge Fund Activity: Q3 2025 in Review
166 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q3 2025, worth a combined $379M — up 19% from $319M a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new ZVRA positions and 10 closed out — a net gain of 46 holders — while 52 added to existing stakes and 37 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $10.5M. The largest seller was Adage Capital Partners, cutting an estimated $19.5M.
- 166 institutional investors held Zevra Therapeutics (ZVRA) as of Q3 2025, up from 120 in Q2 2025.
- Funds reported $379M of Zevra Therapeutics stock for Q3 2025, up 19% quarter-over-quarter.
- 56 funds opened new Zevra Therapeutics positions in Q3 2025 and 10 closed out, a net change of +46 holders.
- The largest Zevra Therapeutics buyer in Q3 2025 was Susquehanna International Group, an estimated $10.5M added.
- The largest Zevra Therapeutics seller in Q3 2025 was Adage Capital Partners, an estimated $19.5M sold.
Based on aggregated 13F filings for Q3 2025.